A subcutaneous bispecific T‑cell–engaging antibody that binds CD3 on T cells and CD20 on B cells, forming an immune synapse to activate T cells and mediate cytotoxic killing of malignant B cells.
Bispecific antibody that binds CD3 on T cells and CD20 on B cells, crosslinking them to form an immune synapse that activates T cells and mediates cytotoxic killing of CD20-positive malignant B cells.
Epcoritamab crosslinks CD3 on T cells to CD20 on B cells, forming an immune synapse and activating T cells to kill CD20+ cells via perforin/granzyme-mediated apoptosis.
Humanized IgG1 anti-CD20 monoclonal antibody administered by IV infusion; depletes CD20+ B cells via ADCC, CDC, and apoptosis, reducing B–T cell crosstalk, B-cell cytokine production, and pathogenic humoral responses while largely sparing plasma cells and hematopoietic stem cells.
Humanized IgG1 anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes naïve and memory B cells via ADCC, complement-dependent cytotoxicity, and apoptosis; this reduces antigen presentation, B–T cell crosstalk, B‑cell cytokine production, and pathogenic humoral responses while largely sparing plasma cells and hematopoietic stem cells.
The anti-CD20 IgG1 binds CD20 on B cells and recruits immune effector mechanisms, causing antibody-dependent cellular cytotoxicity via FcγR-bearing cells, complement-dependent cytotoxicity via C1q activation, and apoptosis upon crosslinking
Anti-CD38 IgG1 monoclonal antibody immunotherapy; induces ADCC, ADCP, CDC, direct apoptosis of CD38+ myeloma cells, and inhibits CD38 ectoenzyme–mediated immunosuppression.
Humanized IgG1 anti‑CD38 monoclonal antibody that binds CD38 on myeloma/plasma cells, triggering ADCC, ADCP, and CDC and inducing direct apoptosis; also inhibits CD38 ectoenzyme activity to reduce immunosuppression and enhance immune effector function.
Isatuximab binds CD38 on target cells and triggers Fc-mediated ADCC by NK cells, ADCP by macrophages, complement-dependent cytotoxicity (CDC), and can induce direct apoptosis of CD38+ cells.
Chimeric anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells, reducing autoantibody production and immune-complex/complement activity; used as frontline therapy in membranous nephropathy and MCD/FSGS.
Chimeric anti‑CD20 IgG1 monoclonal antibody that binds CD20 on pre‑B and mature B cells and depletes them via complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis, thereby reducing autoantibody production and immune‑complex/complement‑mediated inflammation.
Rituximab binds CD20 on B cells and induces complement-dependent cytotoxicity (CDC) and Fc-mediated ADCC, causing lysis/apoptosis of CD20+ cells.
Recombinant humanized anti-EGFR monoclonal antibody (IV) that binds EGFR’s extracellular domain to block ligand binding and receptor dimerization, suppress downstream signaling, and may engage Fc-mediated ADCC.
Humanized IgG1 monoclonal antibody against EGFR that binds the receptor’s extracellular domain to block ligand binding and receptor dimerization, inhibiting EGFR-driven signaling and tumor cell proliferation, and may induce Fc-mediated ADCC against EGFR-expressing cells.
IgG1 anti-EGFR antibody engages Fcγ receptors on NK/effector cells to mediate ADCC against EGFR+ cells (and blocks EGFR signaling, inhibiting proliferation).